Brief ReportsA Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum DisorderJoshi, Gagan MD; Wozniak, Janet MD; Faraone, Stephen V. PhD; Fried, Ronna EdD; Chan, James MA; Furtak, Stephannie BA; Grimsley, Emily BS; Conroy, Kristina BA; Kilcullen, J. Ryan BA; Woodworth, K. Yvonne BA; Biederman, Joseph MDAuthor Information From the *Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital; †Department of Psychiatry, Harvard Medical School, Boston, MA; ‡Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, NY; §K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway. Received August 18, 2015; accepted after revision February 19, 2016. Clinical Trials Registration: ClinicalTrials.gov Registration Number: NCT01333865. Reprints: Gagan Joshi, MD, The Alan & Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorder, Massachusetts General Hospital, 55 Fruit St, WRN 625, Boston, MA 02114 (e-mail: [email protected]). Journal of Clinical Psychopharmacology: June 2016 - Volume 36 - Issue 3 - p 262-271 doi: 10.1097/JCP.0000000000000499 Buy Erratum Metrics Abstract This prospective 12-week open-label trial evaluates the tolerability and efficacy of memantine hydrochloride for the treatment of core social and cognitive deficits in adults with high-functioning autism spectrum disorder (ASD). Measures for assessment of therapeutic response included the Social Responsiveness Scale-Adult Research Version (SRS-A), disorder-specific Clinical Global Impression scales, Behavior Rating Inventory of Executive Functioning–Adult Self-Report, Diagnostic Analysis of Nonverbal Accuracy Scale, and Cambridge Neuropsychological Test Automated Battery. Eighteen adults (mean age, 28 ± 9.5 years) with high-functioning ASD (SRS-A raw score, 99 ± 17) were treated with memantine (mean dose, 19.7 ± 1.2 mg/d; range, 15–20 mg), and 17 (94%) completed the trial. Treatment with memantine was associated with significant reduction on informant-rated (SRS-A, −28 ± 25; P < 0.001) and clinician-rated (Clinical Global Impression-Improvement subscale ≤2, 83%) measures of autism severity. In addition, memantine treatment was associated with significant improvement in ADHD and anxiety symptom severity. Significant improvement was noted in nonverbal communication on the Diagnostic Analysis of Nonverbal Accuracy Scale test and in executive function per self-report (Behavior Rating Inventory of Executive Functioning–Adult Self-Report Global Executive Composite, −6 ± 8.8; P < 0.015) and neuropsychological assessments (Cambridge Neuropsychological Test Automated Battery). Memantine treatment was generally well tolerated and was not associated with any serious adverse events. Treatment with memantine appears to be beneficial for the treatment of ASD and associated psychopathology and cognitive dysfunction in intellectually capable adults. Future placebo-controlled trials are warranted. Erratum The authors of an article published in the June 2016 issue of the Journal of Clinical Psychopharmacology notified us that they would like to add additional disclosures for Gagan Joshi, MD. Additional Author Disclosure Information – Gagan Joshi, MD: In addition to being supported by the National Institute of Mental Health of the National Institutes of Health under award number K23MH100450, Dr Gagan Joshi receives research support from Pfizer and the Simons Center for the Social Brain as a principal investigator (PI) for investigator-initiated studies. He also receives research support from Duke University and Sunovion Pharmaceuticals as a site PI for multi-site trials. Dr Joshi is a co-investigator for a clinical trial sponsored by the U.S. Department of Defense. He received an honorarium from the Governor's Council for Medical Research and Treatment of Autism in New Jersey for grant review activities and speaker’s honorariums from the American Academy of Child and Adolescent Psychiatry, Massachusetts General Hospital Psychiatry Academy, and the Medical Society of Delaware. Journal of Clinical Psychopharmacology. 36(4):339, August 2016. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.